Business Wire

NJ-DAIICHI-SANKYO

9.12.2022 14:01:33 CET | Business Wire | Press release

Share
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials

Updated results from the TROPION-PanTumor01 phase 1 trial showed datopotamab deruxtecan (Dato-DXd) continued to demonstrate encouraging responses in patients with heavily pretreated metastatic triple negative breast cancer (TNBC) and disease progression following standard treatment. Results were presented today as a poster presentation (Abstract #P6-10-03) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Approximately 15% of breast cancers are considered triple negative and are associated with higher disease recurrence and worse prognosis compared to other breast cancer subtypes.1,2 It is estimated that only 12% of patients with metastatic TNBC survive five years after diagnosis and median overall survival is between 12 to 18 months.1,3

In the TNBC cohort of TROPION-PanTumor01 (n=44) where patients previously received a median of three lines of treatment for metastatic disease, datopotamab deruxtecan demonstrated an objective response rate (ORR) of 32%, including one complete response (CR), 13 partial responses (PRs) and 18 cases of stable disease (SD) as assessed by blinded independent central review (BICR). In a subgroup of 27 patients who had not been previously treated with topoisomerase I inhibitor-based ADCs, the ORR was 44% including one CR, 11 PRs and 10 cases of SD. The median duration of response (DoR) was 16.8 months (95% confidence interval [CI]: 5.6-NE) across patient groups.

“Triple negative breast cancer is the most aggressive subtype of breast cancer with the average survival rate of less than 18 months for patients with pretreated metastatic disease,” said Aditya Bardia, MD, MPH, Director of Breast Cancer Research Program, Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. “The durable tumor response and disease control seen with datopotamab deruxtecan in patients with pretreated triple negative breast cancer are encouraging, particularly in those patients who had not received previous treatment with topoisomerase I inhibitor-based antibody drug conjugate.”

In the overall cohort, datopotamab deruxtecan demonstrated median progression-free survival (PFS) of 4.4 months (95% CI: 3.0-7.3) and median overall survival (OS) of 13.5 months (95% CI: 10.1-16.3). In the subgroup of patients who had not been previously treated with a topoisomerase I inhibitor, median PFS and OS were 7.3 months (95% CI: 3.0-18.0) and 14.3 months (95% CI: 10.5-NE), respectively. The disease control rate (DCR) was consistent across the overall cohort and previously untreated subgroup at 80% and 81%, respectively.

The safety profile of datopotamab deruxtecan was consistent with previously reported data with no new safety signals identified. The most common grade 3 or higher treatment-emergent adverse events (TEAEs) were stomatitis (11%), decreased lymphocyte count (7%), fatigue (7%), vomiting (5%), anemia (2%), decreased neutrophil count (2%) and nausea (2%). Serious TEAEs were reported in nine patients (20.5%). Treatment discontinuations occurred in one patient (2%) due to grade 1 pneumonitis, which was adjudicated as not treatment-related interstitial lung disease (ILD). No cases of ILD were observed. No cases of febrile neutropenia or grade 3 or higher diarrhea were observed.

“Five-year survival rates for previously treated metastatic triple negative breast cancer are significantly lower than other subtypes of breast cancer, underscoring the need for new, durable therapies,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo. “We are working with urgency and care to evaluate datopotamab deruxtecan in multiple treatment settings in phase 3 trials, including the TROPION-Breast02 first-line phase 3 trial in patients with locally recurrent inoperable or metastatic triple negative breast cancer not candidates for anti-PD-L1 therapy.”

“The median duration of response of nearly 17 months seen in the TROPION-PanTumor01 trial in these patients reinforces the potential of datopotamab deruxtecan to treat this persistent disease,” said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. “These results, along with the promising clinical response in combination with durvalumab seen in the BEGONIA trial, underscore the potential role of this TROP2 directed antibody drug conjugate for patients with triple negative breast cancer as both a monotherapy and in combinations.”

Patients in the TROPION-PanTumor01 trial were heavily pretreated, receiving a median of three prior regimens in the metastatic setting (range, 1-10). Prior treatments included taxanes (93%), anthracyclines (75%), capecitabine (61%), platinum-based chemotherapy (52%), immunotherapy (45%), topoisomerase I inhibitor-based ADCs (32%) and PARP inhibitors (18%). As of data cut-off on July 22, 2022, three patients remained on study treatment.

Summary of TROPION-PanTumor01 Results in Metastatic TNBC

Efficacy Measure

All TNBC Patients
[n=44 (6 mg/kg, n=42;
8 mg/kg, n=2)]

 

Patients Without Prior Topoisomerase I
Inhibitor-Based ADC
[n=27 (6 mg/kg, n=25; 8 mg/kg, n=2)]

Confirmed ORR, %i,ii

32% (n=14)

44% (n=12)

CR, %

2% (n=1)

4% (n=1)

PR, %

30% (n=13)

41% (n=11)

SD, %

41% (n=18)

37% (n=10)

Non-CR/non-PD, %

7% (n=3)

0

PD, %

18% (n=8)

15% (n=4)

NE, %

2% (n=1)

4% (n=1)

DCR, %i,iii

80% (n=35)

81% (n=22)

Median DoR (months) (95% CI)i

16.8 months (5.6-NE)

16.8 months (5.6-NE)

Median PFS (months) (95% CI)i

4.4 months (3.0-7.3)

7.3 months (3.0-18.0)

Median OS (months) (95% CI)

13.5 months (10.1-16.3)

14.3 months (10.5-NE)

CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; NE, not evaluable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease

iAs assessed by BICR

iiORR is (CR + PR)

iiiDCR is (CR+PR+SD+non-CR/non-PD)

BEGONIA Arm 7 Updated Results
Updated results from the BEGONIA phase 1b/2 trial (n=61) showed datopotamab deruxtecan in combination with durvalumab, AstraZeneca’s immune checkpoint inhibitor, demonstrated an ORR of 73.6% (95% CI: 59.7-84.7) in patients with previously untreated unresectable, locally advanced or metastatic TNBC as assessed by investigator. Among the 53 evaluable patients, there were four CRs and 35 PRs. Responses were observed regardless of PD-L1 expression (low and high tumors) with 82% of patients continuing to respond at the time of data cut-off on July 22, 2022. These data were presented as a Spotlight Poster Discussion (abstract #PD11-09) at SABCS on December 8.

The safety profile of datopotamab deruxtecan in combination with durvalumab was consistent with the known safety profiles of both agents. The most common all-grade TEAEs occurring in 20% or more of patients were nausea (57.4%), stomatitis (55.7%), alopecia (45.9%), fatigue (39.3%), constipation (39.3%), rash (27.9%) and vomiting (21.3%). Serious TEAEs were observed in 10 (16.4%) patients. Treatment discontinuations due to an adverse event occurred in four patients (6.6%). Two (3.3%) cases were adjudicated as treatment-related grade 1 ILD.

Twenty-five patients (41.0%) had not received prior treatment for metastatic TNBC. Prior treatments for patients with disease progression following treatment for early-stage disease included radiotherapy (49.2%), anthracyclines (45.9%), taxanes (41.0%), platinum-based chemotherapy (14.8%), hormonal therapy (14.8%) and targeted therapy (4.9%). Seven (11.5%) patients had high PD-L1 expression (tumor area positivity [TAP]≥10%) and 53 patients (86.9%) had low PD-L1 expression (TAP<10%). At data cut-off, 45 patients remained on study treatment.

Daiichi Sankyo and AstraZeneca have a broad clinical development program for datopotamab deruxtecan in TNBC, including the recently initiated global TROPION-Breast03 phase 3 trial evaluating datopotamab deruxtecan with and without durvalumab in patients with stage 1 to 3 TNBC with residual disease after neoadjuvant therapy. The first patients were enrolled in November 2022 and are expected to be dosed in December 2022. SWOG Cancer Research Network Clinical Trials Partnerships (SWOG CTP) is the lead academic group for the trial and a key collaborator in its protocol development, US site selection and planned recruitment and analysis.

About TROPION-PanTumor01
TROPION-PanTumor01 is a first-in-human, open-label, two-part, multicenter phase 1 trial evaluating the safety and preliminary efficacy of datopotamab deruxtecan in patients with advanced solid tumors that have relapsed or are refractory to standard treatment or for which no standard treatment is available. The dose escalation portion of the trial enrolled patients with non-small cell lung cancer (NSCLC) to assess the safety and efficacy of datopotamab deruxtecan to determine the recommended dose for expansion (6 mg/kg). The dose expansion part of TROPION-PanTumor01 is enrolling several different cohorts including patients with NSCLC, TNBC, HR positive, HER2 low or negative breast cancer, small cell lung cancer, urothelial, gastric, pancreatic, castration resistant prostate and esophageal cancer.

Safety endpoints include dose-limiting toxicities and serious adverse events. Efficacy endpoints include ORR, DoR, time to response, PFS and OS. Pharmacokinetic, biomarker and immunogenicity endpoints also are being evaluated.

About BEGONIA
BEGONIA is an open-label, two-part, multicenter phase 1b/2 trial evaluating durvalumab in combination with oncology therapies with or without paclitaxel for the first-line treatment of metastatic TNBC. Arm 7 of the trial is evaluating the safety, tolerability and preliminary efficacy of datopotamab deruxtecan in combination with durvalumab in patients with previously untreated, unresectable locally advanced or metastatic TNBC.

The primary endpoints are safety and tolerability. The secondary endpoints include investigator-assessed ORR, PFS, DoR and OS.

About Triple Negative Breast Cancer
Breast cancer is the most common cancer and one of the leading causes of cancer-related deaths worldwide.4 More than two million breast cancer cases were diagnosed in 2020 with nearly 685,000 deaths globally.4

Approximately 15% of breast cancers are considered triple negative, which is defined by tumors that test negative for estrogen and progesterone hormone receptors (HRs) and low or negative for human epidermal growth factor 2 receptor (HER2), as determined by an immunohistochemistry (IHC) test and/or an in-situ hybridization (ISH) test.1 Tumors with HER2 expression measured as IHC 0 are considered HER2 negative and tumors with HER2 expression measured as IHC 1+ or IHC 2+/ISH- are considered HER2 low.1,5 TNBC is considered the most aggressive subtype of breast cancer.1,2 Compared to patients with other breast cancer subtypes, the prognosis for patients with metastatic TNBC is generally worse with a five-year survival rate estimated at 12% and a median overall survival rate of 12 to 18 months.1,3

TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is broadly expressed in several types of solid tumors, including approximately 80% of patients with TNBC.6,7,8 TROP2 expression is an unfavorable prognostic factor for overall survival in all types of breast cancer.8

About Datopotamab Deruxtecan (Dato-DXd)
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.

A comprehensive development program called TROPION is underway globally with more than 10 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple TROP2 targetable tumors, including NSCLC, TNBC and HR positive, HER2 low or negative breast cancer. Trials in combination with other anticancer treatments, such as immunotherapy, are also underway.

About the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for the manufacturing and supply of datopotamab deruxtecan.

About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

References:

1 National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes. Accessed December 2022.
2 O’Reilly D, et al. World J Clin Oncol. 2021; 12(3):164-182.
3 Sharma P. et al. Oncologist. 2016;21(9):1050–1062.
4 Sung H, et al. CA Cancer J Clin. 2021;10.3322/caac.21660.
5 Iqbal N, et al. Mol Biol Int. 2014;852748.
6 Goldenberg D, et al. Oncotarget. 2018;9(48): 28989-29006.
7 Ambrogi F, et al. PLoS One. 2014;9(5):e96993.
8 Zaman S, et al. Onco Targets Ther. 2019;12:1781-1790.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005562/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release

Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release

Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release

ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release

Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release

Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye